文献速递前列腺癌

氟-18标记的前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描或磁共振成像用于诊断和定位前列腺癌:一项前瞻性单臂配对比较(PEDAL)

Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
PubMed 文献 · Eur Urol Oncol · 2024-01-27

这项前瞻性多中心单臂3期影像试验纳入临床怀疑前列腺癌患者,比较18F-DCFPyL PSMA-PET/CT与mpMRI活检诊断准确性;mpMRI诊断前列腺癌的AUC 0.76高于PSMA-PET/CT的AUC 0.63(p=0.03),但检出临床显著前列腺癌无显著差异(p=0.27);两者联合敏感性98.8%、NPV 96%。

要点

  • mpMRI诊断前列腺癌AUC 0.76高于PSMA-PET/CT AUC 0.63(p=0.03)。
  • 检出临床显著前列腺癌两者AUC无显著差异(p=0.27)。
  • 联合PSMA-PET/CT与mpMRI敏感性98.8%、NPV 96%,优于mpMRI单用(p=0.01)。

核心结论

  • mpMRI检测前列腺癌的诊断准确性优于PSMA-PET/CT,但在检测临床显著前列腺癌时差异无统计学显著性。
  • mpMRI与PSMA-PET/CT联合显示更高的敏感性和阴性预测值。
  • 对于无法接受mpMRI或临床特征可疑但mpMRI阴性的患者,可考虑将PSMA-PET/CT用于诊断。

研究设计与样本

  • 2020年至2021年开展的前瞻性多中心单臂3期影像试验,纳入临床怀疑前列腺癌患者,同时接受mpMRI和PSMA-PET/CT(胸部至大腿),阅片者对另一影像结果设盲。
  • mpMRI阳性定义为前列腺影像报告和数据系统(PIRADS)3-5分;PSMA-PET/CT采用定量(阳性最大标准化摄取值SUVmax >7)和定性(五点确定性词典)评估。
  • 患者接受靶向和系统活检,技术由治疗泌尿外科医生决定;临床显著前列腺癌(csPCa)定义为国际泌尿病理学会分级组(GG)≥2。
  • 236例患者完成mpMRI和PSMA-PET/CT,其中184例(76.7%)接受活检;活检组织学良性73例、GG 1级27例、GG ≥2级84例。

主要发现

  • mpMRI检测前列腺癌的AUC为0.76(95%CI 0.69, 0.82),高于PSMA-PET/CT的AUC 0.63(95%CI 0.56, 0.70),p=0.03。
  • mpMRI检测csPCa的AUC为0.72(95%CI 0.67, 0.78),高于PSMA-PET/CT的AUC 0.62(95%CI 0.55, 0.69),但未达统计学显著(p=0.27)。
  • PSMA-PET/CT与mpMRI联合的敏感性为98.8%(95%CI 93.5%, 100%),NPV为96%(95%CI 79.6%, 99.9%),优于mpMRI单用(敏感性86.9%、NPV 80.7%),p=0.01。
  • 32例患者(13.6%)有转移性疾病,其年龄更大(68.4 vs 65.1岁,p=0.023),前列腺特异性抗原更高(中位PSA 9.6 vs 6.2 ng/ml,p<0.001),直肠指检前列腺异常比例更高(78.2% vs 44.1%,p<0.001)。

关键数值与推荐

  • mpMRI阳性定义为PIRADS 3-5分;PSMA-PET/CT阳性定量标准为SUVmax >7。
  • csPCa定义为ISUP分级组≥2。
  • 主要终点为检测前列腺癌的诊断准确性,报告敏感性、特异性、NPV和ROC曲线下面积(AUC)。

临床怎么用

  • 对于无法接受mpMRI或临床特征可疑但mpMRI阴性的患者,可考虑将PSMA-PET/CT用于诊断。
  • mpMRI与PSMA-PET/CT联合可提高阴性预测值,可能帮助男性避免侵入性前列腺活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Multiparametric magnetic resonance imaging (mpMRI) of the prostate is used for prostate cancer diagnosis. However, mpMRI has lower sensitivity for small tumours. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) offers increased sensitivity over conventional imaging. This study aims to determine whether the diagnostic accuracy of 18F-DCFPyL PSMA-PET/CT was superior to that of mpMRI for detecting prostate cancer (PCa) at biopsy. METHODS: Between 2020 and 2021, a prospective multicentre single-arm phase 3 imaging trial enrolled patients with clinical suspicion for PCa to have both mpMRI and PSMA-PET/CT (thorax to thigh), with reviewers blinded to the results of other imaging. Multiparametric MRI was considered positive for Prostate Imaging Reporting and Data System (PIRADS) 3-5. PSMA-PET/CT was assessed quantitatively (positive maximum standardised uptake value [SUVmax] >7) and qualitatively (five-point lexicon of certainty). Patients underwent targeted and systematic biopsy, with the technique at the discretion of the treating urologist. Clinically significant PCa (csPCa) was defined as International Society of Urological Pathology grade group (GG) ≥2. The primary outcome was the diagnostic accuracy for detecting PCa, reported as sensitivity, specificity, negative predictive value (NPV), and area under the curve (AUC) of the receiver operating curve. The secondary endpoints included a comparison of the diagnostic accuracy for detecting csPCa, assessing gains in combining PMSA-PET/CT with mpMRI to mpMRI alone. KEY FINDINGS AND LIMITATIONS: Of the 236 patients completing both mpMRI and PSMA-PET/CT, 184 (76.7%) had biopsy. Biopsy histology was benign (n = 73), GG 1 (n = 27), and GG ≥2 (n = 84). The diagnostic accuracy of mpMRI for detecting PCa (AUC 0.76; 95% confidence interval [CI] 0.69, 0.82) was higher than that of PSMA-PET/CT (AUC 0.63; 95% CI 0.56, 0.70, p = 0.03). The diagnostic accuracy of mpMRI for detecting csPCa (AUC 0.72; 95% CI 0.67, 0.78) was higher than that of PSMA-PET/CT (AUC 0.62; 95% CI 0.55, 0.69) but not statistically significant (p = 0.27). A combination of PSMA-PET/CT and mpMRI showed excellent sensitivity (98.8%, 95% CI 93.5%, 100%) and NPV (96%, 95% CI 79.6%, 99.9%) over mpMRI alone (86.9% and 80.7%, respectively, p = 0.01). Thirty-two patients (13.6%) had metastatic disease. They tended to be older (68.4 vs 65.1 yr, p = 0.023), and have higher prostate-specific antigen (PSA; median PSA 9.6 vs 6.2ng/ml, p < 0.001) and abnormal prostate on digital rectal examination (78.2% vs 44.1%, p < 0.001). CONCLUSIONS AND CLINICAL IMPLICATIONS: Multiparametric MRI had superior diagnostic accuracy to PSMA-PET/CT for detecting PCa, though the difference is not significant in case of csPCa detection. A combination of mpMRI and PSMA-PET/CT showed improved sensitivity and NPV. PSMA-PET/CT could be considered for diagnostic use in patients unable to have mpMRI or those with concerning clinical features but negative mpMRI. PATIENT SUMMARY: In this trial, we compared the ability of 18F-labelled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) with that of multiparametric magnetic resonance imaging (mpMRI) to diagnose prostate cancer by biopsy in a prostate-specific antigen screening population. We found that MRI was superior to PSMA to diagnose prostate cancer, though there was no difference in ability to diagnose clinically significant prostate cancer. PSMA-PET/CT could be considered for diagnostic use in patients unable to have mpMRI or those with concerning clinical features but negative mpMRI. Combining MRI with PSMA-PET increases the negative predictive value over MRI alone and may help men avoid invasive prostate biopsy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wong LM, Sutherland T, Perry E, et al. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). Eur Urol Oncol. 2024. PMID: 38281891. doi:10.1016/j.euo.2024.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。